Hoppa till innehåll
Attgeno

Attgeno

Meny

  • About us
    • The Attgeno organisation
    • Board of Directors
    • Management Team
    • Mission & Vision
    • History
  • Our Science
  • Disease Areas
  • Pipeline
  • News
  • Contact

    2020, Apr

    Second financial round oversubscribed rights issue

    Attgeno completes second rights MSEK 20, oversubscribed with 49%

    2020, Apr
    attgenoadmin april, 2020mars, 2021 R&D2
    • ← Clinical phase 1 FIH study approved by Swedish MPA
    • The Supernitro project was granted MSEK 5 in support from Vinnova →
    Attgeno

    Home of Supernitro

    Contact us

    Attgeno AB
    Fogdevreten 2A
    171 65 Solna

    SWEDEN

    Phone +46 70 645 78 27

    E-mail info@attgeno.com

    Attgeno

    • About us
      • The Attgeno organisation
      • Board of Directors
      • Management Team
      • Mission & Vision
      • History
    • Our Science
    • Disease Areas
    • Pipeline
    • News
    • Contact
    Upphovsrätt © 2024 Attgeno. Drivs med WordPress. Tema: Spacious av ThemeGrill.